SIRT2 and colorectal cancer: To identify the global landscape of the SIRT2 acetylome, we performed label-free quantitative proteomic analysis following enrichment for acetylated peptides using an anti-acetyl lysine antibody from SIRT2-depleted and SIRT2-overexpressing HCT116 human colorectal cancer cells using liquid chromatography-tandem mass spectrometry (LC–MS/MS) (Fig. 1a–f).